Renca Syngeneic Murine Model

Renca Syngeneic Model
Validated Renca Syngeneic Model by Altogen Labs

RENCA syngeneic murine model

Renca cell line refers to a line of cancer cells that was originally isolated from a kidney tumor in a Balb/c mouse. These cells are commonly used in cancer research as a model for studying renal cell carcinoma. The Renca cell line is considered a highly aggressive and invasive cancer cell line, which can be used to investigate tumor progression, metastasis, and potential treatments for renal cell carcinoma. The Renca cell line has been extensively studied in animal models and in vitro experiments, and has been shown to be responsive to various chemotherapy agents, immunotherapies, and targeted therapies. Kidney cancer is responsible for more than 338,000 new cases diagnosed annually worldwide and for over 13,000 fatalities every year in the United States alone, as stated by the American Cancer Society. Renal cell carcinoma (RCC) comprises nearly 85 percent of all kidney malignancies. Despite the development of targeted therapies, many patients develop resistance and eventually die of the disease. Innovative therapeutic approaches are required to improve the outcomes of RCC patients. Preclinical studies of renal syngeneic animal models aid scientists in finding new therapies for RCC patients. The Renca tumorigenic epithelial cell line is derived from a kidney adenocarcinoma of Balb/c-Cr mice. Renca cells spontaneously metastasize to lung and liver, mimicking human renal cell carcinoma. A 2016 study in Cancer Science investigates the therapeutic efficacy of the combination of the mTOR inhibitor everolimus (EVE) and anti‐PD‐L1. The study demonstrates that anti‐PD‐L1 treatment enhances the antitumor effect of EVE in a mouse model, which is beneficial for the treatment of RCC. In 1997 Kadhim et al. published a study using Renca cells in mouse models to characterize the antitumor activity of BCH-4556, a nucleoside analogue; results demonstrated tumor shrinkage, tumor growth inhibition and tumor cell cytotoxicity.  BCH-4556 was later renamed as trxacitabine and progressed to phase II clinical trials. In 2011 Lavranos et al. presented data using a Renca orthotopic syngeneic model to demonstrate the antitumor effects of BNC105, a vascular disruption agent; data demonstrated the drug affects tumor, but not normal vasculature formation. As of 2017 BNC105 progressed to a clinical combination therapy trial with Keytruda, a PD-1 inhibitor also known as Pembrolizumab. For a final example of a research study using the Renca mouse model, Hirayama et al. (2016) demonstrated that immunotherapy against programmed cell death-1 (PD-1) and its ligand PD-L1 can be combined with the mTOR inhibitor treatment everolumus (EVE) and result in significantly decreaed tumor burden, increased tumor infiltrating lymphocytes (TILs) and higher ratio of cytotoxic CD8+ T-cells to TILs, supporting this combination therapy as a potential clinical treatment for renal cell carcinoma. The Renca cell line (mouse kidney) is used to create the Renca syngeneic murine model. The Renca syngeneic murine model is a kidney cancer model utilized for studying inhibition of angiogenesis (e.g. BAI1), JAK kinase inhibitors (e.g. AZD1480) and antitumor efficacy (e.g. imidazoquinoline).

Download Altogen Labs Renca Syngeneic Murine Model PowerPoint Presentation: PPT2

Basic study design

  1. Renca cells are trypsinized, and then cell viability is determined (trypan blue assay; 98-99% cell viability minimum).  After adjusting the concentration of the cell suspension to 10,000 cells per µL (Matrigel + Renca cells), 10-week-old athymic BALB/C or NOD/SCID mice are injected.  All tumors are grown in the rear, hind leg flank via subcutaneous injections.
  2. Injection sites are checked (3 x per week) until tumors are established.  Continual tumor measurement (with digital calipers) is followed until average sizes of 120-150 mm3 is determined. At this point, tumor size randomization into treatment cohorts and in-life administration of compounds are performed.
  3. All tumors are measured daily and mouse body weights are recorded.  Mice are euthanized as the size limits are reached.  All tissue collections are performed at the final necropsy, including tissues being snap frozen, prepared for histology or stabilized (RNA-later reagent). Dissected tumors are documented (digital imaging) and weights are recorded.

Get Instant Quote for
Renca Xenograft Model

Syngeneic murine models are used to assess the effectiveness of drugs against specific types of cancer. New medicines are tested on staged tumor growths that have been engrafted via subcutaneous or orthotopic inoculation in an immunocompromised mouse or rat model. All clinically approved anti-cancer agents have been evaluated with conventional nonclinical in vivo models. Subcutaneous and metastatic studies can be highly complex, starting with the selection of the appropriate animal model, choice of tumorigenic cell line, administration method, dosing, analysis of tumor growth rates and tumor analysis (histology, mRNA, and protein expression levels).

Animal handling and maintenance at the Altogen Labs facilities are IACUC regulated and GLP compliant. Following acclimation to the vivarium environment, mice are sorted according to body mass. The animals are examined daily for tumor appearance and clinical signs. Additional services available include collection of tissue, histology, isolation of total protein or RNA and analysis of gene expression. Our animal facilities have the flexibility to use specialized food or water systems for inducible gene expression systems.

The following options are available for the Renca syngeneic murine model:

  • Renca Tumor Growth Delay (TGD; latency)
  • Renca Tumor Growth Inhibition (TGI)
  • Dosing frequency and duration of dose administration
  • Dosing route (intravenous, intratracheal, continuous infusion, intraperitoneal, intratumoral, oral gavage, topical, intramuscular, subcutaneous, intranasal, using cutting-edge micro-injection techniques and pump-controlled IV injection)
  • Renca tumor immunohistochemistry
  • Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
  • Blood chemistry analysis
  • Toxicity and survival (optional: performing a broad health observation program)
  • Gross necropsies and histopathology
  • Positive control group employing cyclophosphamide, at a dosage of 20-25 mg/kg
  • Lipid distribution and metabolic assays

Get Instant Quote for
Renca Xenograft Model